Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:
This study has been terminated.
(low enrollment low enrollment)
Information provided by (Responsible Party):
Timothy Damron, M.D., State University of New York - Upstate Medical University
First received: February 1, 2008
Last updated: May 29, 2013
Last verified: May 2013
Researchers have previously demonstrated loss of heterozygosity in a region on chromosome 18q, associated with osteogenic sarcomas in bone affected by Paget's disease. The loci used in this study are specifically described by those authors as showing loss of heterozygosity in 6 of 7 affected families.
||Observational Model: Family-Based
Time Perspective: Prospective
||Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: Examination of Osteosarcoma Tissue Samples From Two Family Members for Loss of Heterozygosity in the Chromosome 18 Region, Genetically Linked With Paget's Disease of Bone
Biospecimen Retention: Samples With DNA
Primary Outcome Measures:
Once a specimen is obtained DNA will be isolated for paraffin-embedded tissue and peripheral blood. Osteosarcoma samples from paraffin embedded, formalin-fixed post-surgical tissue samples will be obtained for the proband and father. Matched normal spamples will be obtained from these individuals as adjacent normal tissue from the post-surgical specimens
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2009 (Final data collection date for primary outcome measure)
family members of the proband and father identified
As above, no additional information
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
This is a familial study therefore the only inclusion/exclusion criteria would be that subjects must be a blood relative and over the age of 18. The subjects are proband and father along with unaffected blood relatives. Their peripheral blood will act as a control and provide information to delineate the inheritance from the father, as seen in the son.
- This is a familial study therefore the only inclusion/exclusion criteria would be that subjects must be a blood relative and over the age of 18.
- The subjects are proband and father along with unaffected blood relatives. Their peripheral blood will act as a control and provide information to delineate the inheritance from the father, as seen in the son.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00615628
|SUNY Upstate Medical University
|Syracuse, New York, United States, 13202 |
State University of New York - Upstate Medical University
||Timothy A Damron, MD
||State University of New York - Upstate Medical University
No publications provided
||Timothy Damron, M.D., Associate Professor, State University of New York - Upstate Medical University
History of Changes
|Other Study ID Numbers:
||Osteosarcoma & Paget's Disease, IRB #4168
|Study First Received:
||February 1, 2008
||May 29, 2013
||United States: Institutional Review Board
Keywords provided by State University of New York - Upstate Medical University:
Inheritance of Osteosarcoma & Paget's Disease through Chromosome 18
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 15, 2014
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type